Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UQQ2
UPID:
SH2B3_HUMAN
Alternative names:
Lymphocyte adapter protein; Lymphocyte-specific adapter protein Lnk; Signal transduction protein Lnk
Alternative UPACC:
Q9UQQ2; B9EGG5; O95184
Background:
SH2B adapter protein 3, also known as Lymphocyte adapter protein, plays a pivotal role in linking T-cell receptor activation signal to key signaling pathways, including phospholipase C-gamma-1, GRB2, and phosphatidylinositol 3-kinase. Its involvement in immune response modulation and signal transduction underscores its significance in cellular functions.
Therapeutic significance:
The protein's association with diseases such as Celiac disease 13 and Type 1 diabetes mellitus highlights its potential as a target for therapeutic intervention. Understanding the role of SH2B adapter protein 3 in these conditions could pave the way for novel treatments aimed at modulating immune responses and improving patient outcomes.